Researchers from the University of Birmingham (UoB) and the University of Naples Federico II have found that a sequence of ...

Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic ...

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, ...

Psoriatic arthritis is a combination of psoriasis and arthritis symptoms. You may have skin and nail changes, joint pain and ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...

In individuals with psoriasis, the immune system malfunctions, causing inflammatory cells to accumulate in the dermis, the ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...

Delays in diagnosing and treating psoriatic arthritis – a common inflammatory disorder affecting 112 in every 100,000 adults – are causing irreparable ...

Your doctor might recommend this if your joints become severely damaged ... and help people with PsA access the latest treatments. The National Psoriasis Foundation has resources on clinical ...

Certain psoriasis treatments can cause liver toxicity ... or stiffness in the joints close relatives with psoriasis recent illnesses or stressful life events In some cases, they may do a biopsy ...

Anyone who watches television has heard the list of potential adverse reactions, considering that commercials for psoriasis treatments are ... relief to the skin and joints. For milder cases ...

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...